Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Director | May 21, 2026 | May 22, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 04, 2026 | February 06, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | PRESIDENT AND HEAD OF R&D | August 16, 2023 | August 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21 | Direct | 15,000 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000 F1: Options will vest in full on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest in full on the anniversary of the grant date.
Syndax Pharmaceuticals Inc
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,000 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 103,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Xilio Therapeutics, Inc.
Report date August 16, 2023 · Filed August 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2033-08-15 | Direct | 136,500 |
Reported balance
After 2023-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-16 · Grant · Acquired 136,500 · Balance 136,500 F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mersana Therapeutics, Inc.
Report date January 06, 2026 · Filed January 06, 2026
Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Other · Disposed 9,573 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-06 · Disposition to issuer · Disposed 5,938 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-06 · Disposition to issuer · Disposed 26,713 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.25 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-06 · Disposition to issuer · Disposed 1,923 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-06 · Disposition to issuer · Disposed 99 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-06 · Disposition to issuer · Disposed 407 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.25 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-06 · Disposition to issuer · Disposed 135 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-06 · Disposition to issuer · Disposed 179 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-01-06 · Disposition to issuer · Disposed 12,121 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-01-06 · Disposition to issuer · Disposed 27,878 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-01-06 · Disposition to issuer · Disposed 364 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-01-06 · Disposition to issuer · Disposed 497 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-01-06 · Disposition to issuer · Disposed 7,467 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-01-06 · Disposition to issuer · Disposed 13,340 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-01-06 · Disposition to issuer · Disposed 1,328 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-01-06 · Disposition to issuer · Disposed 7,256 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 12,206 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 8,750 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 4,447 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 22,727 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.14 · Expires 2025-09-21 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-22 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-22 · Disposition to issuer · Disposed 10,782 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-22 · Disposition to issuer · Disposed 39,942 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:03 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004243 · ownership.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 21:55 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041344 · ownership.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 7,256 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 19 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,256 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 1,328 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 18 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,328 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 13,340 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 17 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,340 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 7,467 | Not disclosed Strike: $75.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 16 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,467 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 497 | Not disclosed Strike: $75.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 15 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 497 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 364 | Not disclosed Strike: $31.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 14 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 364 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 27,878 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 13 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,878 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 12,121 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 12 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,121 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 179 | Not disclosed Strike: $85.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 11 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 179 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 734 | Not disclosed Strike: $216.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 10 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 135 | Not disclosed Strike: $106.25 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 9 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,800 | Not disclosed Strike: $90.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 8 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 407 | Not disclosed Strike: $161.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 7 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 407 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,002 | Not disclosed Strike: $372.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 6 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,002 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 99 | Not disclosed Strike: $527.25 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 5 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,923 | Not disclosed Strike: $214.25 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 4 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,923 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 26,713 | Not disclosed Strike: $16.01 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,713 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 5,938 | Not disclosed Strike: $16.01 | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · derivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,938 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:47 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | OtherCommon Stock | 9,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-001376 · tm261736-6_4seq1.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 20:26 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 2,012 | $7.31 | $14,707.72 |
DisclosureSEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,572 F3 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.22 to $7.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 20:26 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,340 Underlying: Common Stock · 20,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. F6 · derivative.exercise_date: 25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years. F6 · derivative.expiration_date: 25% of the total number of RSUs granted vested on September 11, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years. F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 20:26 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090026 · tm2526132-1_4seq1.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on September 11, 2023. F2 · shares: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025. Read SEC document |
| May 19, 2025 Filed May 19, 2025 20:02 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 5,000 | $8.99 | $44,950.00 |
DisclosureSEC source: 0000950170-25-074297 · ownership.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,000 Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:34 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016351 · ownership.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 00:21 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 4,514 | $0.58 | $2,618.12 |
DisclosureSEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,875 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:21 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Unit · Derivative | 181,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 5 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,400 Underlying: Common Stock · 181,400 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant. F7 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:21 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (Right to Buy) · Derivative | 816,300 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 4 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 816,300 Underlying: Common Stock · 816,300 shares Expires 2035-01-14 F6 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:21 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 11,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,188 Underlying: Common Stock · 11,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F5 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years. F5 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:21 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 11,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004593 · tm253733-4_4seq1.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2024. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:08 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 50,423 | $1.76 | $88,744.48 |
DisclosureSEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · nonDerivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,327 F3 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.735 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 21:08 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 166,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · derivative · entry 3 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,250 Underlying: Common Stock · 166,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: 25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years. F6 · derivative.expiration_date: 25% of the RSUs granted vested on September 11, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 21:08 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 166,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-099855 · tm2424033-2_4seq1.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on September 11, 2023. F2 · balance_after: On June 12, 2023, the Reporting Person filed a Form 4 reporting the award of a RSU award representing the right to receive 14,467 shares of common stock of the Issuer on June 8, 2023. Such RSU award was subsequently rescinded in connection with the Reporting Person's appointment as president and chief executive officer effective in September 2023 and as a result was cancelled for no value. The amount of securities beneficially owned reported in this Form 4 reflects an adjustment in the number of shares held by the Reporting Person, reflecting the cancellation of the June 8, 2023 RSU award for no value. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001220 · primarydocument.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:19 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Unit · Derivative | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004545 · tm243529-4_4seq1.xml · derivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 44,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant. F3 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:19 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (Right to Buy) · Derivative | 199,125 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001104659-24-004545 · tm243529-4_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,125 Underlying: Common Stock · 199,125 shares Expires 2034-01-14 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:31 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 9,102 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001104659-23-106843 · tm2327613-5_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,102 Underlying: Common Stock · 9,102 shares Expires 2033-10-01 F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for non-employee director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $9,557.69 for service as a non-employee director between July 1, 2023 and September 10, 2023 in the quarter ended September 30, 2023. F2 · derivative.exercise_date: Fully vested as of the date of grant. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 20:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted stock unit · Derivative | 667,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-100441 · tm2326002-1_4seq1.xml · derivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,000 Underlying: Common Stock · 667,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 20:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001104659-23-100441 · tm2326002-1_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2033-09-10 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on the first anniversary of the grant, and the remainder shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 00:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 136,500 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012415 · form4-08182023_080801.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,500 Underlying: Common Stock · 136,500 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 4,477 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001104659-23-078752 · tm2320657-3_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,477 Underlying: Common Stock · 4,477 shares Expires 2033-07-02 F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $12,250 for the quarter ended June 30, 2023. F2 · derivative.exercise_date: Fully vested as of the date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 18,355 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001104659-23-070362 · tm2318463-4_4seq1.xml · derivative · entry 2 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,355 Underlying: Common Stock · 18,355 shares Expires 2033-06-07 F2 · derivative.exercise_date: The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantCommon Stock | 14,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-070362 · tm2318463-4_4seq1.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,467 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents the contingent right to receive one share of Common Stock of the Issuer. F2 · shares: The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:15 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 3,375 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001104659-23-042244 · tm2311858-4_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,375 Underlying: Common Stock · 3,375 shares Expires 2033-04-02 F1 · shares: This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $11,000 for the quarter ended March 31, 2023. F2 · derivative.exercise_date: Fully vested as of the date of grant Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:56 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000946 · primarydocument.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:11 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 136,500 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001415889-23-000289 · form4-01042023_090139.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,500 Underlying: Common Stock · 136,500 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option award was granted on January 1, 2023 and shall vest on February 1, 2023 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:31 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006747 · form4-06172022_040644.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and will vest in equal monthly installments until June 15, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 23, 2022 23:30 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006908 · form4a-06232022_070602.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and shall vest on July 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until June 1, 2026. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001104659-22-070138 · tm2218135-2_4seq1.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.